University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Randomized Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Participants in this study have been diagnosed with diffuse large B-cell lymphoma (DLBCL) that has either come back after therapy or that has become worse. The purpose of the study is to evaluate the effectiveness and side effects of treatment with 2 separate doses of the study drug (fostamatinib). The study will also evaluate the drug concentrations in the blood and how it is processed by the body. Study treatment will last as long as participant is receiving a benefit.

Start Date
November 14, 2012
End Date
November 14, 2022
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Lori Rosenstein, MD
Contact Info

Mary Schall, 319-356-3516

cancer ; diffuse large B-cell lymphoma (DLBCL) ; fostamatinib ; IRB#201207502 ; phase 2 ; phase II ; rosenstein ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.